Two Onc Docs

Dive into the intricate world of bone sarcomas as the hosts break down vital topics like diagnosis, staging, and treatment strategies. Explore the unique characteristics of osteosarcoma and Ewing's sarcoma, highlighting the importance of personalized therapies. Discover how genetic mutations influence treatment plans and the critical role of surgical interventions. With a focus on the latest chemotherapy protocols and emerging systemic treatments, this discussion sheds light on a challenging yet fascinating area of oncology.

Delve into the latest insights on soft tissue sarcomas, featuring new FDA approvals and evolving diagnostic challenges. Discover the complexities of this rare category of tumors, which represent just 1% of adult cancers and include both noncancerous and aggressive forms. Learn about treatment strategies for various subtypes, including desmoid tumors and Kaposi's sarcoma, highlighting innovative surgical and chemotherapy advancements. The emphasis is on a multidisciplinary approach to enhance patient outcomes.

Dive into the world of Thrombotic Thrombocytopenic Purpura (TTP) with high-yield facts on its mechanisms, symptoms, and treatment strategies. Explore the urgency of prompt diagnosis and how plasmapheresis can save lives. Learn about Hemolytic Uremic Syndrome (HUS), especially its impact on children and the critical need for early intervention. The discussion covers risk factors and treatment options, making it essential knowledge for both medical professionals and anyone interested in understanding these serious conditions.

This week dives deep into gastric adenocarcinoma, discussing risk factors like H. pylori infections and the importance of genetic testing. The latest staging techniques, including EGD and biopsies, are detailed for managing advanced cases. Advances in treatment are highlighted, with a focus on the newly approved zolbituximab for metastatic cases. The use of immunotherapy for specific genetic profiles is also explored, alongside ongoing clinical trial impacts and future directions in gastric cancer care.

We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Join oncologists Dr. Tom Powles and Dr. Brian Rini as they dive into the latest strategies for managing metastatic renal cell carcinoma. They discuss the importance of risk stratification and patient characteristics in treatment selection. The conversation covers the evolving role of cytoreductive nephrectomy, the significance of immunotherapy breaks, and the complexities of side effects from tyrosine kinase inhibitors. Listen for insights on tailored approaches for various RCC subtypes and career advice for budding oncologists!

Join renowned oncologists Tom Powles, a leading expert in GU oncology from Barts Cancer Center, and Brian Rini, a pioneer in clinical trials at Vanderbilt, as they delve into the latest insights on localized renal cell carcinoma. They explore critical risk factors, including smoking and genetic conditions like von Hippel-Lindau syndrome. The duo examines evolving treatment strategies, including nephrectomy, ablative techniques, and the emerging role of immune therapies, shedding light on their potential impacts on patient outcomes.

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome. 

Delve into the groundbreaking MATTERHORN trial, where the synergy of durvalumab and the FLOT regimen offers new hope for resectable gastric cancer. Learn about the exciting results presented at the ASCO 2025 plenary session and how these findings could reshape future treatments. The discussion also explores current standards of care and the potential impact pending further research and FDA approval. This session highlights the innovative intersection of immunotherapy and conventional approaches in oncology.